Biological Collection on Emerging Infectious Diseases and Their Treatments (COMETE)
A Biological Sample Collection Established to Support Pathophysiological Research on Emerging and Potentially Emerging Infectious Diseases, as Well as Their Therapeutic Management.
Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs). Advances in the treatment of cancers, malignant haematological disorders and immune-mediated inflammatory diseases are also contributing to the creation of new infectious risks among immunocompromised patient populations.
The COVID-19 pandemic has shown that structuring research prior to any outbreak is essential for the rapid implementation of responses to the emergence of an EID. The unpredictability of an EID's occurrence necessitates the planning of research projects in advance. A key element in this planning is the development of a collection of biological samples, providing a structured and immediately deployable resource for conducting pathophysiological and therapeutic research aimed at:
- Analyze the biological determinants of the microbe and the resulting infection
- Develop new tools for identification and characterization
- Study the factors (biomarkers/signatures) associated with individual patient susceptibility and response to treatment (personalized medicine)
- Understand the pathophysiology of infection to identify new targets for diagnostic, curative and preventive treatment
- Monitor the efficacy of curative and preventive treatments
研究概览
详细说明
COMETE consists in a prospective monocenter longitudinal non-interventional study allowing the collection of biological samples from individuals or patients investigated in the context of an emerging infectious disease or one at risk of emergence due to exposure or suggestive symptomatology, whether the infection is ultimately ruled out or confirmed, and whether or not they have received curative or preventive treatment for this infection.
Visits: The initial visit (inclusion) and follow-up visits will take place as part of the patient's routine care, assessing their disease status or the curative or preventive treatment received during either hospitalization or a consultation. During these visits, biological samples will be collected when sampling is planned as part of the care (for verification, suspicion, diagnosis, or monitoring), and then throughout the follow-up period as part of the care plan.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Guillaume MARTIN-BLONDEL, MD, PhD
- 电话号码：33 +33561779699
- 邮箱：martin-blondel.g@chu-toulouse.fr
研究联系人备份
- 姓名：Béatrice PIGNOLET, PhD
- 电话号码：33 +33561779975
- 邮箱：pignolet.b@chu-toulouse.fr
学习地点
-
-
-
Toulouse、法国、31059
- University Hospital toulouse
-
接触：
- Guillaume MARTIN-BLONDEL, MD, PhD
- 电话号码：33 +33561779699
- 邮箱：martin-blondel.g@chu-toulouse.fr
-
接触：
- Béatrice PIGNOLET, PhD
- 电话号码：33 +33561779975
- 邮箱：pignolet.b@chu-toulouse.fr
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Patients aged 18 years or over
- Patients or individuals who have been exposed, are at risk of exposure, or are at risk of complications if exposed, or who are suspected of having, or are diagnosed with, an infectious disease considered to be emerging or at risk of emerging
- Patients receiving, or likely to receive, innovative treatments for the infection (new therapeutic molecules, checkpoint inhibitors, cell therapies, etc.)
- Patients or individuals receiving, or likely to receive, vaccines or other preventive therapeutic strategies
- Pregnant and breastfeeding women may be included.
Exclusion Criteria:
- Patients under a legal guardianship arrangement (guardianship, curatorship or court-ordered guardianship)
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
Subjects presenting with emerging or potentially emerging infectious diseases
Biological samples will be collected in the normal diagnosis and follow-up process (only blood will be collected in larger quantity)
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Collection of biological samples and associated data from patients at risk of acquiring, or affected by, emerging or potentially emerging infectious diseases, including those receiving preventive or curative treatment for such infections
大体时间：through study completion, an average of 1 year
|
Prospective collection of all available biological and clinical-biological-imaging data collected during the usual clinical care
|
through study completion, an average of 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To improve our understanding of the pathophysiology of infection in order to identify new biomarkers for diagnostic and prognostic purposes, with a view to improving the management of emerging infectious diseases or those at risk of emerging
大体时间：through study completion, an average of 1 year
|
Identification of biomarkers using collected biological samples obtained from patients for cohort studies with various methods (flow cytometry, -omics, …)
|
through study completion, an average of 1 year
|
|
Identify new therapeutic targets for curative or preventive treatments
大体时间：through study completion, an average of 1 year
|
Identification of therapeutic targets using collected biological samples obtained from patients for cohort studies with various methods (flow cytometry, -omics, …)
|
through study completion, an average of 1 year
|
|
At the pathogen level: Analyse the biological determinants of the microbe and the resulting infection
大体时间：through study completion, an average of 1 year
|
Identification of biological determinants of the microbe and the resulting infection using collected biological samples with various methods of screening (PCR, qPCR, sequencing, metagenomics)
|
through study completion, an average of 1 year
|
|
At the pathogen level: Develop new tools for identification and characterisation
大体时间：through study completion, an average of 1 year
|
Use of the biological samples obtained from patients for using new and innovative methods of screening (PCR, qPCR, sequencing, metagenomics)
|
through study completion, an average of 1 year
|
|
At the host level: Identification and/or validation of associated or predictive biomarkers
大体时间：through study completion, an average of 1 year
|
Use of collected biological samples obtained from patients for cohort studies with various methods (flow cytometry, -omics, …)
|
through study completion, an average of 1 year
|
合作者和调查者
调查人员
- 首席研究员：Guillaume MARTIN-BLONDEL, MD, PhD、University Hospital, Toulouse
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- RC31/25/0195
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.